Dr. Reddy's Laboratories Limited
NYSE:RDYDrug Manufacturers - Specialty & Generic
-$0.15 today
- Market cap
- $12.48B
- Beta
- 0.26
- P/E (TTM)
- 24.7
- EPS (TTM)
- $51.40
- Dividend yield
- 0.63%
Volume 1.79M
Average 2.39M
RDY Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Dr. Reddy's Laboratories LimitedNYSE: RDY
Research & Development · Q2 FY2027 · quarter ended Sep 2026
Research & development declines year over year
Q2 FY2027 research & development of ₹5.23B fell 15.7% year over year, behind the -13.8% change in trailing-twelve-month research & development. Sequentially, it fell 9.9% from the prior quarter. Over 3 fiscal years it compounded at +9.3% a year.
Context
- Research & development amounted to 7.2% of revenue in FY2026, down 1.2 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -15.7% toward the trailing-twelve-month pace of -13.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
INR · from the income statement
- Latest · FY2026
- 25.31B INR
- Year-over-year change
- -7.5%
- 4-year CAGR
- +9.7%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2026 | 2026-03-31 | 25.31B | -7.5% |
| FY2025 | 2025-03-31 | 27.38B | +19.7% |
| FY2024 | 2024-03-31 | 22.87B | +18.0% |
| FY2023 | 2023-03-31 | 19.38B | +10.9% |
| FY2022 | 2022-03-31 | 17.48B | — |
Research & Development vs competitors
How RDY compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -13.8% is the 6th highest of 7, against a peer median of +8.6%.
- Research & development amounts to 6.9% of revenue for RDY, versus a peer median of 5.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | ₹22.73B INR | -13.8% | +9.3% | 6.9% | |
| LTM Jun 2026 | $1.02B USD | +20.8% | +13.4% | 6.9% | |
| LTM Jun 2026 | $995M USD | -0.7% | +6.5% | 5.7% | |
| LTM Jun 2026 | $634M USD | +1.3% | +5.9% | 5.8% | |
| LTM Jun 2025 | £459.5M GBP | — | +0.9% | 2.8% | |
| LTM Jun 2026 | $177.66M USD | -15.0% | -3.7% | 5.7% | |
| LTM Mar 2026 | $92.49M USD | +20.2% | +4.7% | 12.8% | |
| LTM Mar 2026 | $51.7M USD | +15.8% | +32.3% | 5.6% | |
| Peer median (excluding RDY) | — | +8.6% | +5.9% | 5.7% | |
Competitors are the stored peer set for RDY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 | FY2026 Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 214.39B | 245.88B | 279.16B | 325.54B | 353.47B |
| Cost of Revenue | 100.55B | 106.54B | 115.56B | 135.11B | 166.95B |
| Gross Profit | 113.84B | 139.34B | 163.61B | 190.43B | 186.52B |
| Gross Margin | 53.1% | 56.7% | 58.6% | 58.5% | 52.8% |
| Research & Development | 17.48B | 19.38B | 22.87B | 27.38B | 25.31B |
| Selling, General & Admin | 62.08B | 68.03B | 77.2B | 93.87B | 112.34B |
| Operating Expenses | 84.36B | 82.2B | 95.88B | 118.59B | 137.65B |
| Depreciation & Amortization | 11.82B | 12.64B | 14.84B | 17.06B | 21.68B |
| EBITDA | 45.08B | 74.43B | 88.42B | 96.67B | 83.29B |
| EBITDA Margin | 21.0% | 30.3% | 31.7% | 29.7% | 23.6% |
| Operating Income | 29.48B | 57.14B | 67.73B | 71.84B | 48.87B |
| Operating Margin | 13.7% | 23.2% | 24.3% | 22.1% | 13.8% |
| Interest Income | 965M | 1.18B | 2.28B | 2.68B | 8.28B |
| Interest Expense | 958M | 1.43B | 1.71B | 2.83B | 3.93B |
| Other Income / Expenses | 2.82B | 3.22B | 4.14B | 4.94B | 8.81B |
| Income Before Tax | 32.3B | 60.37B | 71.87B | 76.78B | 57.68B |
| Pre-Tax Margin | 15.1% | 24.6% | 25.7% | 23.6% | 16.3% |
| Income Tax Expense | 8.73B | 15.3B | 16.19B | 19.54B | 13B |
| Net Income | 23.57B | 45.07B | 55.68B | 56.54B | 45.09B |
| Net Margin | 11.0% | 18.3% | 19.9% | 17.4% | 12.8% |
| EPS (Basic) | 28.42 | 54.29 | 66.80 | 67.85 | 53.92 |
| EPS (Diluted) | 28.34 | 54.17 | 66.80 | 67.77 | 53.92 |
| Weighted Avg Shares | 829.41M | 830.17M | 833.54M | 833.31M | 832.41M |
| Weighted Avg Shares (Diluted) | 831.69M | 831.91M | 833.54M | 834.3M | 833.26M |
Dr. Reddy's Laboratories Limited
NYSE:RDY
Intrinsic Alpha fair value
Locked
Current Price
$14.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.